Amyloid heart disease: Genetics translated into disease-modifying therapy

Heart

Volumn 103, Issue 11, 2017, Pages 812-817

  Sperry, Brett W ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; ACTIVATING TRANSCRIPTION FACTOR 6 ALPHA; ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; PATISIRAN; PREALBUMIN; REVUSIRAN; SMALL INTERFERING RNA; TAFAMIDIS; UNCLASSIFIED DRUG;

APOPTOSIS; ATTR AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARPAL TUNNEL SYNDROME; CHROMOSOME 18; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART AMYLOIDOSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; PROTEIN MISFOLDING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; TREATMENT OUTCOME; TTR GENE; AMYLOIDOSIS; CARDIOMYOPATHIES; GENE THERAPY; GENETICS; PROCEDURES;

AMYLOIDOSIS; CARDIOMYOPATHIES; GENETIC THERAPY; HUMANS;

EID: 85019120184     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-309914     Document Type: Review

References (56)

1. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-7.
2. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 2016;214:477-81.
3. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8.
4. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
5. Bokhari S, Castaño A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
6. Sperry BW, Jones BM, Vranian MN, et al. Recognizing Transthyretin cardiac Amyloidosis in Patients with aortic Stenosis: Impact on Prognosis. JACC Cardiovasc Imaging 2016;9:904-6.
7. Thomas PK. Genetic factors in amyloidosis. J Med Genet 1975;12:317-26.
8. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404-12.
9. Senapati A, Sperry BW, Grodin JL, et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 2016;102:748-54.
10. Sperry BW, Vranian MN, Hachamovitch R, et al. Subtype-Specific Interactions and Prognosis in cardiac Amyloidosis. J Am Heart Assoc 2016;5:e002877.
11. Maurer MS, Hanna M, Grogan M, et al. THAOS Investigators. Genotype and Phenotype of Transthyretin cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 2016;68:161-72.
12. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
13. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73.
14. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127-36.
15. Buxbaum J, Alexander A, Koziol J, et al. Significance of the amyloidogenic transthyretin Val 122 ile allele in african Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 2010;159:864-70.
16. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015;372:21-9.
17. Dungu JN, Papadopoulou SA, Wykes K, et al. Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. Circ Heart Fail 2016;9.
18. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
19. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-27.
20. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086-97.
21. Suhr OB, Lindqvist P, Olofsson BO, et al. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 2006;13:154-9.
22. Drugge U, Andersson R, Chizari F, et al. Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis. J Med Genet 1993;30:388-92.
23. Hosoi A, Su Y, Torikai M, et al. Novel Antibody for the Treatment of Transthyretin Amyloidosis. J Biol Chem 2016;291:25096-105.
24. Gustavsson A, Engström U, Westermark P. Mechanisms of transthyretin amyloidogenesis. antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994;144:1301-11.
25. Desport E, Bridoux F, Sirac C, et al. Centre national de référence pour l'amylose AL et les autres maladies par dépôts d'immunoglobulines monoclonales. Al Amyloidosis. Orphanet J Rare Dis 2012;7:54.
26. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
27. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
28. Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain variable region germline gene use in AL Amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 1999;106:744-51.
29. Perfetti V, Palladini G, Casarini S, et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2012;119:144-50.
30. Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005;105:794-803.
31. Benson MD, Liepnieks JJ, Kluve-Beckerman B. Hereditary systemic immunoglobulin light-chain amyloidosis. Blood 2015;125:3281-6.
32. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8:519-26.
33. Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 2016;23:86-97.
34. Galant NJ, Bugyei-Twum A, Rakhit R, et al. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep 2016;6:25080.
35. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93-7.
36. Richards DB, Cookson LM, Berges AC, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med 2015;373:1106-14.
37. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6.
38. Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 2016;23:109-18.
39. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819-29.
40. Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015;10:109.
41. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts 2014;5:45-54.
42. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006;33:609-18.
43. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19 Suppl 1(Suppl 1):43-4.
44. Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 2016;23:148-57.
45. Benson MD, Ackermann EJ, Monia BP. Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis. Orphanet J Rare Dis 2015;10(P7Suppl 1.
46. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients presenting with symptomatic Heart Failure. J Am Coll Cardiol 2016;67:2941-8.
47. Dey BR, Chung SS, Spitzer TR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010;90:905-11.
48. Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol 2016;91:947-56.
49. Ohno S, Yoshimoto M, Honda S, et al. The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002;169:4039-45.
50. Phipps JE, Kestler DP, Foster JS, et al. Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol 2010;38:1006-13.
51. Hovey BM, Ward JE, Soo Hoo P, et al. Preclinical development of siRNA therapeutics for AL Amyloidosis. Gene Ther 2011;18:1150-6.
52. Zhou P, Ma X, Iyer L, et al. One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood 2014;123:3440-51.
53. Kluve-Beckerman B, Hardwick J, Du L, et al. Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid 2011;18:136-46.
54. Chen JJ, Genereux JC, Qu S, et al. ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein. Chem Biol 2014;21:1564-74.
55. Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014;136:16958-61.
56. Vranian MN, Sperry BW, Valent J, et al. Emerging Advances in the Management of cardiac Amyloidosis. Curr Cardiol Rep 2015;17:100.